IRIS
FERRO, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.464
NA - Nord America 4.683
EU - Europa 3.492
SA - Sud America 696
Continente sconosciuto - Info sul continente non disponibili 201
AF - Africa 163
OC - Oceania 12
Totale 15.711
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.447
SG - Singapore 2.660
RU - Federazione Russa 1.689
CN - Cina 1.335
VN - Vietnam 1.192
IT - Italia 657
BR - Brasile 547
HK - Hong Kong 353
DE - Germania 257
BD - Bangladesh 236
FR - Francia 190
IN - India 179
GB - Regno Unito 149
NL - Olanda 138
FI - Finlandia 132
JP - Giappone 127
CA - Canada 109
KR - Corea 104
MX - Messico 67
AR - Argentina 60
IE - Irlanda 45
CI - Costa d'Avorio 40
PL - Polonia 40
ZA - Sudafrica 39
IQ - Iraq 36
TH - Thailandia 36
AT - Austria 30
SE - Svezia 29
PH - Filippine 28
UA - Ucraina 27
ID - Indonesia 25
ES - Italia 23
EC - Ecuador 21
TR - Turchia 20
PK - Pakistan 16
KE - Kenya 15
PY - Paraguay 15
CO - Colombia 14
JM - Giamaica 13
JO - Giordania 13
LT - Lituania 13
VE - Venezuela 13
TW - Taiwan 11
UZ - Uzbekistan 11
EG - Egitto 10
CL - Cile 9
DK - Danimarca 9
IL - Israele 9
MY - Malesia 9
PE - Perù 9
TN - Tunisia 9
AZ - Azerbaigian 8
CZ - Repubblica Ceca 8
NP - Nepal 8
AE - Emirati Arabi Uniti 7
BE - Belgio 7
NG - Nigeria 7
AU - Australia 6
DZ - Algeria 6
PT - Portogallo 6
BG - Bulgaria 5
CH - Svizzera 5
DO - Repubblica Dominicana 5
HN - Honduras 5
LV - Lettonia 5
MA - Marocco 5
NI - Nicaragua 5
OM - Oman 5
RO - Romania 5
AO - Angola 4
BB - Barbados 4
BO - Bolivia 4
ET - Etiopia 4
GT - Guatemala 4
IR - Iran 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LC - Santa Lucia 4
NZ - Nuova Zelanda 4
PA - Panama 4
RS - Serbia 4
SA - Arabia Saudita 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
GR - Grecia 3
AL - Albania 2
AM - Armenia 2
BH - Bahrain 2
BS - Bahamas 2
CR - Costa Rica 2
CV - Capo Verde 2
CW - ???statistics.table.value.countryCode.CW??? 2
CY - Cipro 2
GA - Gabon 2
LB - Libano 2
LK - Sri Lanka 2
MK - Macedonia 2
MT - Malta 2
NA - Namibia 2
PR - Porto Rico 2
Totale 15.466
Salva come PNG Salva come JPEG
Città #
Singapore 1.373
San Jose 893
Ashburn 557
Hefei 469
Moscow 390
Beijing 344
Hong Kong 338
Ho Chi Minh City 324
Hanoi 231
Chandler 203
Santa Clara 193
Los Angeles 179
Naples 164
New York 126
Lauterbourg 121
Amsterdam 107
Tokyo 104
Munich 102
Dong Ket 96
Kochi 87
Seoul 84
The Dalles 82
Dallas 69
Buffalo 65
Council Bluffs 60
Redondo Beach 60
São Paulo 60
Milan 56
Da Nang 55
Turku 54
Frankfurt am Main 44
Millbury 44
Boston 43
Orem 43
Enfield 41
Des Moines 36
Mexico City 36
Brooklyn 34
Seattle 34
Rome 33
Haiphong 32
Warsaw 32
Nuremberg 31
Atlanta 30
London 30
Princeton 30
Houston 29
Lappeenranta 29
Montreal 29
Helsinki 28
Nanjing 28
Phoenix 28
Denver 27
Chicago 26
Toronto 24
Johannesburg 23
Chennai 22
Lawrence 22
Bari 19
Washington 19
Biên Hòa 18
Dublin 18
Düsseldorf 18
Napoli 18
Ninh Bình 18
Stockholm 18
Ottawa 17
Charlotte 15
Poplar 15
San Francisco 15
Wilmington 15
Baghdad 14
Casamassima 14
Rio de Janeiro 13
Vienna 13
Can Tho 12
Nairobi 12
Phủ Lý 12
Thái Bình 12
Turin 12
Amman 11
Bangkok 11
Belo Horizonte 11
Brasília 11
Dearborn 11
Florence 11
Newark 11
Philadelphia 11
Shanghai 11
Tianjin 11
Boardman 10
Buenos Aires 10
Manchester 10
Querétaro 10
Bengaluru 9
Changsha 9
Dhaka 9
Guangzhou 9
Hebei 9
Mumbai 9
Totale 8.475
Salva come PNG Salva come JPEG
Nome #
The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial 291
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets 209
Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials 174
Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL 169
Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer 169
Urinary Micro-RNAs As Biomarkers of Urological Cancers: A Systematic Review 167
Advances in Urinary Diversion: From Cutaneous Ureterostomy to Orthotopic Neobladder Reconstruction-A Comprehensive Review 167
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer 164
The Role of Butirprost® as an Adjuvant in Enhancing the Effect of Antibiotics in Patients Affected by Chronic Bacterial Prostatitis: A Randomized Prospective Trial 158
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients 157
Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance 155
Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients. 151
Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis 151
Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. 150
The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review 149
The Impact of Meat Intake on Bladder Cancer Incidence: Is It Really a Relevant Risk? 149
Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading 149
Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine 148
Ablative Treatments for Small Renal Masses and Management of Recurrences: A Comprehensive Review 147
Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers 147
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis 147
Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: Systematic review and meta-analysis 146
Biomarkers in localized prostate cancer 146
Artificial Intelligence and Machine Learning in Prostate Cancer Patient Management-Current Trends and Future Perspectives 146
Modified glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical Cystectomy: A multicenter experience 145
Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer 145
Epigenetic signature: A new player as predictor of clinically significant prostate cancer (PCa) in patients on active surveillance (AS) 144
Predictors of residual T1 high grade on re-transurethral resection in a large multi-institutional cohort of patients with primary T1 high-grade/grade 3 bladder cancer 144
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy 144
Which inflammatory marker, between systemic immune-inflammation index and neutrophil to eosinophil ratio, is associated with Peyronie's disease and are there any implications for a better understanding of its mechanisms? 144
Reliability of Multiparametric Magnetic Resonance Imaging in Patients with a Previous Negative Biopsy: Comparison with Biopsy-Naïve Patients in the Detection of Clinically Significant Prostate Cancer 143
Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol 143
Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study 142
Exploring the Multifactorial Landscape of Penile Cancer: A Comprehensive Analysis of Risk Factors 141
New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index 140
Subcellular Localization of uc.8+ as a Prognostic Biomarker in Bladder Cancer Tissue 139
Neutrophil, platelets, and eosinophil to lymphocyte ratios predict gleason score upgrading in low-risk prostate cancer patients 137
Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone 137
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer 136
Peri-Prostatic Adipocyte-Released TGFβ Enhances Prostate Cancer Cell Motility by Upregulation of Connective Tissue Growth Factor 135
Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy 134
High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study 134
Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database 132
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study 132
Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions 131
Soluble interleukin-6 receptor to interleukin-6 (sIL-6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy 131
Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance 131
The evolving landscape of renal surgery for complex renal masses (CRM): implications for oncologic and functional outcomes 130
Optimized Identification of High-Grade Prostate Cancer by Combining Different PSA Molecular Forms and PSA Density in a Deep Learning Model 130
Unlocking Precision Medicine: Liquid Biopsy Advancements in Renal Cancer Detection and Monitoring 129
The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review 129
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States 128
Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG 127
Salvage radical prostatectomy after external beam radiation therapy: A systematic review of current approaches 127
Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma 126
Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF‐1 upregulation of TUBB2B beta‐tubulin isoform 126
Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review 125
The European Network for the Study of Adrenal Tumors Staging System (2015): A United States Validation 124
Early and late post-procedural complications in different orthotopic neobladder surgical approaches: A systematic review 124
The emerging role of obesity, diet and lipid metabolism in prostate cancer 124
Urologic malignancies: advances in the analysis and interpretation of clinical findings 124
Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies 124
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer 123
Predicting pathological features at radical prostatectomy in patients with prostate cancer eligible for active surveillance by multiparametric magnetic resonance imaging 123
New Cross-Talk Layer between Ultraconserved Non-Coding RNAs, MicroRNAs and Polycomb Protein YY1 in Bladder Cancer 123
Robot-assisted Partial Nephrectomy: 5-yr Oncological Outcomes at a Single European Tertiary Cancer Center 123
Novel Key Ingredients in Urinary Tract Health-The Role of D-mannose, Chondroitin Sulphate, Hyaluronic Acid, and N-acetylcysteine in Urinary Tract Infections (Uroial PLUS®) 122
Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy 122
Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor 122
Management of the incidental adrenal mass, continued surveillance versus surgical excision: analysis of US claims data on contemporary socio-demographic predictors and perioperative outcomes 121
Outcomes and Techniques of Robotic-Assisted Partial Nephrectomy (RAPN) for Renal Hilar Masses: A Comprehensive Systematic Review 121
Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification 121
Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies 121
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy 121
SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study 121
Radiomics in prostate cancer: an up-to-date review 119
Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma 118
Critical Appraisal of Leibovich 2018 and GRANT Models for Prediction of Cancer-Specific Survival in Non-Metastatic Chromophobe Renal Cell Carcinoma 118
Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. 118
Upper Tract Urothelial Cancer: Guideline of Guidelines 116
The Correlation Between Body Mass Index and Prostate Volume: A Retrospective Analysis of Pre and Postoperative Measurements in Prostate Cancer Patients 115
Liquid Biopsy: Current advancements in clinical practice for bladder cancer 114
The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy-naive patients, according to the localization of the lesion at the mpMRI: A single-center retrospective observational study 114
Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma 114
The Role of MUC1 in Renal Cell Carcinoma 113
Patient Selection for Active Surveillance in the Multi-parametric Magnetic Resonance Imaging Era: A Step Forward in a Rapidly Evolving Field 111
Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality–free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients 110
Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice 110
Comparison Between a New PSA Assay With the Well-Established Beckman Coulter Immunoassay: A Preliminary Report 107
FABP4-mediated ERK phosphorylation promotes renal cancer cell migration 107
Artificial intelligence and radiomics applications in adrenal lesions: a systematic review 106
A Neural Network Model Combining [-2]proPSA, freePSA, Total PSA, Cathepsin D, and Thrombospondin-1 Showed Increased Accuracy in the Identification of Clinically Significant Prostate Cancer 104
Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: a double-blind placebo-controlled trial on prostate vascularity 104
Assessing the influence of smoking on inflammatory markers in bacillus Calmette Guérin response among bladder cancer patients: a novel machine-learning approach 102
Enhanced prognostic value of four-tier hybrid grading system in Ta non-muscle-invasive bladder cancer 102
Emerging Biomarkers in Bladder Cancer: Translating Molecular Advances into Precision Oncology 101
The use of 68Ga prostate-specific membrane antigen PET-CT in prostate cancer: diagnostic challenges and therapeutic opportunities 101
Minimally invasive surgical therapies (MISTs) for lower urinary tract symptoms (LUTS): promise or panacea? 100
Circular RNAs: An emerging type of non-coding RNA and their potential implications in bladder cancer 99
Antioxidant treatment for oligoasthenoteratozoospermia and varicocele: a DBPC trial to evaluate the impact of age and body mass index 98
Totale 13.292
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.461
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.461
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022329 0 4 2 0 6 3 6 12 30 39 108 119
2022/2023649 54 25 24 19 77 64 4 52 82 171 72 5
2023/2024551 10 75 100 39 29 56 10 72 7 8 90 55
2024/20253.821 135 148 21 55 168 136 352 211 334 475 1.487 299
2025/20269.345 854 911 961 939 1.382 402 972 582 1.042 576 333 391
2026/2027537 488 49 0 0 0 0 0 0 0 0 0 0
Totale 15.711